Here's What Analysts Think About Telix Pharmaceuticals (TLX)

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 30, TD Cowen lowered its price target on Telix Pharmaceuticals Limited (NASDAQ:TLX) from AUD 35 to AUD 25 but kept its Buy rating on the stock.

Earlier, on December 14, RBC Capital also initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX), assigning the stock a Sector Perform rating and setting the price target at AUD 17. The firm noted that Telix Pharmaceuticals Limited (NASDAQ:TLX) is a radiopharmaceutical company that has successfully commercialized two diagnostic products for prostate cancer. The company has significant potential to expand into other indications.

The research firm highlighted the company’s extensive portfolio and pipeline of assets in urology, neurology, musculoskeletal, and hematologic oncology, which the company is making efforts to commercialize.

While RBC Capital acknowledges these opportunities, it expects Telix Pharmaceuticals Limited’s (NASDAQ:TLX) earnings and free cash flow to remain largely flat between fiscal years 2025 and 2027 as the company focuses on its research and development pipeline.

Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that specializes in therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company is focused on developing clinical and commercial stage products to address significant unmet medical needs in oncology and rare diseases.

While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best US Penny Stocks to Buy and 10 Best New Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.